Pfizer has announced the results of its Phase 2/3 Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) interim ana...
Pfizer has announced the results of its Phase 2/3 Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) interim analysis, revealing that its antiviral pill Paxlovid reduced the risk of hospitalization and death by 89-percent in high-risk adults who had COVID-19. The protective effect was compared to a group of patients who received a placebo drug, paving the way … Continue reading
from SlashGear https://ift.tt/3kaNZaK
via IFTTT
from SlashGear https://ift.tt/3kaNZaK
via IFTTT
COMMENTS